Accessibility StatementSkip Navigation  Preeminent SOL-backed treasury vehicle - with potential to deliver over $1.25 billion - unlocks capital markets to accelerate Solana's growth NEWTOWN, Pa., Sept. 15, 2025 /PRNewswire/ -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company") today announced the pricing of an oversubscribed private investment in public equity offering (the "Offering") for the purchase and sale of common stock (and/or pre-funded warrants to purchase shares of comm ...

Core Points - Helius Medical Technologies, Inc. has demonstrated compliance with the equity requirement for continued listing on the Nasdaq Capital Market as of July 7, 2025 [1] - The company previously regained compliance with the minimum bid price requirement on June 3, 2025, and is currently in full compliance with Nasdaq's continued listing requirements [2] - Helius will be subject to a Mandatory Panel Monitor for one year following the compliance notice [3] Company Overview - Helius Medical Technologies is a neurotech company focused on addressing neurologic deficits through a novel therapeutic neuromodulation approach [4] - The company's primary product is the Portable Neuromodulation Stimulator, which aims to enhance the brain's ability to engage compensatory mechanisms and promote neuroplasticity [4]